Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
According to clinical and pathological factors the prognosis of a patient with non-muscle invasive bladder tumors can be assessed. The prognosis is determined by the likelihood of recurrence(30-70%) and/or progression to muscle invasive bladder cancer(1-15%).Trans urethral resection of bladder tumor...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
TheScientificWorldJOURNAL
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917213/ https://www.ncbi.nlm.nih.gov/pubmed/17619738 http://dx.doi.org/10.1100/tsw.2006.403 |
_version_ | 1783317154717761536 |
---|---|
author | van der Meijden, A.P.M. |
author_facet | van der Meijden, A.P.M. |
author_sort | van der Meijden, A.P.M. |
collection | PubMed |
description | According to clinical and pathological factors the prognosis of a patient with non-muscle invasive bladder tumors can be assessed. The prognosis is determined by the likelihood of recurrence(30-70%) and/or progression to muscle invasive bladder cancer(1-15%).Trans urethral resection of bladder tumors remains the initial therapy but adjuvant intravesical instillations are necessary.All patients benefit from a single immediate post operative instillation with a chemotherapeutic agent and for low risk tumors this is the optimal therapy.Patients with intermediate and high risk tumors need more intravesical chemo-or immunotherapy. Chemotherapy reduces recurrences but not progression. Intravesical immunotherapy(BCG) prevents or delays progression. Patients at high risk for progression may need upfront cystectomy. |
format | Online Article Text |
id | pubmed-5917213 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | TheScientificWorldJOURNAL |
record_format | MEDLINE/PubMed |
spelling | pubmed-59172132018-06-03 Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer van der Meijden, A.P.M. ScientificWorldJournal Review Article According to clinical and pathological factors the prognosis of a patient with non-muscle invasive bladder tumors can be assessed. The prognosis is determined by the likelihood of recurrence(30-70%) and/or progression to muscle invasive bladder cancer(1-15%).Trans urethral resection of bladder tumors remains the initial therapy but adjuvant intravesical instillations are necessary.All patients benefit from a single immediate post operative instillation with a chemotherapeutic agent and for low risk tumors this is the optimal therapy.Patients with intermediate and high risk tumors need more intravesical chemo-or immunotherapy. Chemotherapy reduces recurrences but not progression. Intravesical immunotherapy(BCG) prevents or delays progression. Patients at high risk for progression may need upfront cystectomy. TheScientificWorldJOURNAL 2006-03-09 /pmc/articles/PMC5917213/ /pubmed/17619738 http://dx.doi.org/10.1100/tsw.2006.403 Text en Copyright © 2006 A.P.M. van der Meijden. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article van der Meijden, A.P.M. Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer |
title | Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer |
title_full | Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer |
title_fullStr | Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer |
title_full_unstemmed | Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer |
title_short | Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer |
title_sort | optimal treatment for intermediate- and high-risk, nonmuscle-invasive bladder cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917213/ https://www.ncbi.nlm.nih.gov/pubmed/17619738 http://dx.doi.org/10.1100/tsw.2006.403 |
work_keys_str_mv | AT vandermeijdenapm optimaltreatmentforintermediateandhighrisknonmuscleinvasivebladdercancer |